Related Experiment Video
Updated: Jun 4, 2026
04:29
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Pharmacotherapy for late-life depression.
1Department of Psychiatry, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY, USA.
The Journal of Clinical Psychiatry
|January 29, 2011
Summary
Treatment for geriatric major depressive disorder (MDD) combines antidepressants and psychotherapy. While selective serotonin reuptake inhibitors are effective, more research is needed for other treatments in the elderly.
Area of Science:
- Geriatric psychiatry
- Clinical psychology
- Pharmacology
Background:
- The 2001 expert consensus recommended combining antidepressant medication with psychotherapy for geriatric major depressive disorder (MDD).
- Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) remain first-line treatments for older adults with depression.
- The efficacy of transdermal selegiline, a monoamine oxidase inhibitor, has not been evaluated in geriatric depression.
Discussion:
- Augmentation strategies, including atypical antipsychotics, may benefit elderly patients with agitated, psychotic, or treatment-resistant MDD.
- Studies since 2001 have yielded mixed results, often confounded by high placebo response rates in geriatric populations.
- Evidence for specific pharmacological interventions beyond SSRIs/SNRIs in elderly MDD is limited.
Key Insights:
- Combination therapy (antidepressants + psychotherapy) is a cornerstone for geriatric MDD.
- SSRIs and SNRIs are established first-line agents for depression in older adults.
- Further investigation is required for novel agents and augmentation strategies in this demographic.
Outlook:
- Future research should focus on large, controlled trials to clarify treatment efficacy in geriatric depression.
- Investigating the role of agents like selegiline in older adults is warranted.
- Understanding and mitigating high placebo response rates in geriatric depression trials is crucial for advancing treatment options.
More Related Videos
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
07:58Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
Published on: February 24, 2023
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...